$4450
$3560
The patient-derived xenograft model market size is projected to reach US$ 1,119.36 million by 2031 from US$ 468.75 million in 2024. The market is expected to register a CAGR of 13.5% during 2025–2031.
Patient-Derived Xenograft Model Market Analysis
The?????? need for patient-derived xenograft (PDX) models worldwide is largely influenced by the increasing number of oncology pipelines that require more predictive in vivo platforms, the fast development of personalized medicine, which in turn needs patient-specific tumor models, and the growing outsourcing of preclinical testing to specialized CROs offering PDX services on a scalable ??????basis.
Patient-Derived Xenograft Model Market Overview
The global patient-derived xenograft model market is undergoing a significant transformation. Pharmaceutical and biotechnology companies are progressively implementing human-tumor-derived platforms that are more representative. These platforms preserve genetic and microenvironmental features that are not present in traditional cell lines. Coupled with the rise in cancer cases, the demand for precision therapies and regulatory bodies recognizing more translational models, PDX platforms have become indispensable in preclinical drug discovery, biomarker identification, and studying therapy resistance. Their expansion is also supported by the breakthroughs in genomic profiling, use of human-immune-competent hosts, and large patient-tumor tissue repositories.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Patient-Derived Xenograft Model Market: Strategic Insights
Market Size Value in US$ 378.46 million in 2022 Market Size Value by US$ 975.31 million by 2030 Growth rate CAGR of 12.6% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Patient-Derived Xenograft Model Market Drivers and Opportunities
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Patient-Derived Xenograft Model Market: Strategic Insights
| Market Size Value in | US$ 378.46 million in 2022 |
| Market Size Value by | US$ 975.31 million by 2030 |
| Growth rate | CAGR of 12.6% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Drivers:
Rising Prevalence of Cancer:
The increasing number of cancer cases worldwide is a major factor driving the demand for effective preclinical models, such as PDX. Such preclinical models are useful to understand tumor behavior and to test new therapies.Growing Demand for Personalized Medicine:
The need for personalized treatment methods entails the use of models that are accurate and represent the patient's specific tumor, thus leading to increased utilization of PDX models in drug development and therapy optimization.Advancing Research and Development Activities in Oncology:
The growing oncology research and development initiatives at a global scale mainly fuel the use of PDX models in the testing of new drugs and gaining a deeper understanding of cancer biology.
Market Opportunities:
Expansion into Immuno Oncology / Humanized PDX Models:
The insertion of a human immune system into PDX models enables the testing of immunotherapies. This represents a newly developing area in the immuno-oncology sector. As a result, it creates the potential for a significant increase in turnover in this field.Integration with Multi Omics and Digital Pathology:
The integration of PDX models with genomic, proteomic, and digital pathology data serves to enhance tumor profiling and speed up precision medicine research opportunities.Geographic Growth in Emerging Markets:
Increasing healthcare infrastructure and cancer research investments in emerging regions create significant market expansion opportunities for PDX model ??????adoption.
Patient-Derived Xenograft Model Market Report Segmentation Analysis
The patient-derived xenograft model market is segmented into distinct categories to provide a clearer understanding of its operations, growth potential, and current trends. Below is the standard segmentation approach used in industry reports:
By Type:
Rats Model:
The rat PDX model segment is gaining increased attention, as rats offer larger tissue volumes, enhanced anatomical complexity, and suitability for longer-term studies. These factors are very useful for complex tumor types as well as for surgical/pharmacokinetic research.Mice Model:
The mice segment holds a major share of the market. It is influenced by the availability of well-established immunodeficient mouse strains, easier to manipulate genetic information, cost-effectiveness of the process, and wide use of these models in oncology drug development.
By Tumor Type:
Gastrointestinal Tumor Model:
This segment includes PDX models for digestive tract tumors, such as colorectal, gastric, and pancreatic. Their proliferations are largely due to the high incidence rates in these areas and the pressing need for targeted therapies in the treatment of complex GI malignancies.Gynecological Tumor Model:
It comprises PDX models for tumors of female reproductive organs, such as ovarian and endometrial. Its expansion is a result of the increased research focus on women's cancers and the need for more predictive pre-clinical models.Respiratory Tumor Model:
Respiratory tumor model refers to PDX models of lung and other respiratory-tract tumors. This segment is growing rapidly because of a rise in lung cancer incidence and a substantial investment in respiratory oncology research.Other Tumor Model:
It is a collection of the PDX models representing less common or the ones that have been indifferently tumored, such as sarcoma, head & neck, and melanoma. Their growth has been aided by the deepening of the niche oncology areas, the diversification of PDX applications, and the widening of research ??????pipelines.
By Application:
- Preclinical Drug Development
- Biomarker Analysis
- Translating Research
- Biobanking
By End User:
- Pharmaceutical and Biotechnology Companies
- Academics and Research Institutes
- Contract Research Organizations
By Geography:
- North America
- Europe
- Asia Pacific
- South & Central America
- Middle East & Africa
Market Report ScopePatient-Derived Xenograft Model Market Share Analysis by Geography
Asia Pacific is expected to grow the fastest in the next few years. Emerging markets in South America, the Middle East, and Africa have untapped opportunities for PDX providers to expand.
The growth of the patient-derived xenograft model market varies across regions due to factors such as the rising cancer incidence and expanding pharma research and development, combined with government support for precision medicine and cost?effective CRO services. Below is a summary of market share and trends by region:
1. North America
Market Share:
Holds a significant portion of the global marketKey Drivers:
Cancer research has been heavily funded, the biotech/PHARMA industry is mature, and PDX has been broadly adopted.
Trends:
Humanized mouse PDX models are being used increasingly, AI/biomarker workflows are becoming integrated, and CRO outsourcing is expanding.
2. Europe
Market Share:
Substantial market shareKey Drivers:
Rising use of precision medicine, collaboration among translational oncology networks, and an established academic research base.Trends:
Standardization of PDX protocols across countries, an increase in biobanking initiatives, and regulatory focus on reproducibility and ethics.
3. Asia Pacific
Market Share:
Fastest-growing region with a rising market share every year
Key Drivers:
Rapidly increasing cancer incidence, growing investments in healthcare research and development, and the expansion of pharmaceutical and biotech sectors.
Trends:
Newly developed CRO hubs providing PDX services at low prices, local biobank progress, and multinational collaborations for novel cancers.
4. South and Central America
Market Share:
Growing market with steady progress
Key Drivers:
The increasing cancer burden, coupled with improving research infrastructure, is driving a surge in the outsourcing of preclinical model development by global sponsors.
Trends:
Growing use of PDX services, cooperation with international model providers, and the regional tumor models getting more attention.
5. Middle East and Africa
Market Share:
Small market size, growing at a fast pace
Key Drivers:
Increased government investments in precision oncology, more research centers being set up, and a growing number of oncology clinical trials.
Trends:
Use of PDX models in niche projects (e.g., rare tumors, HIV-associated malignancies), regional biobank programs, and infrastructure expansion for translational ??????research.
Patient-Derived Xenograft Model Market Players Density: Understanding Its Impact on Business Dynamics
High Market Density and Competition
Competition is strong due to the presence of established players such as Charles River Laboratories International Inc. and Crown Bioscience Inc. Regional and niche providers add to the competitive landscape across regions.
The high level of competition urges companies to stand out by offering:
- Product Innovation
- Product Approvals
- Compliance with Regulatory Guidelines
Opportunities and Strategic Moves
- Through?????? targeted medicine, the PDX model market can expand in a very promising way. Targeted medicine allows for exact drug testing, and patients across the world can receive the best cancer treatment.
- By agreements, technology upgrades, and the extension of biobanks, companies invest in such models in order to improve the availability and the quality of the models, and to be competitive in the ??????market.
Other companies analyzed during the course of research:
- Biocytogen Pharmaceuticals Co., Ltd
- Certis Oncology Solutions, Inc.
- Champions Oncology, Inc
- Altogen Labs
- Urosphere SAS
- Horizon Discovery Group plc
- Taconic Biosciences Inc.
- Creative Animodel
- Inotiv, Inc.
Patient-Derived Xenograft Model Market News and Recent Developments
GemPharmatech entered a strategic licensing arrangement with Charles River Laboratories.
The partnership involves the exclusive distribution rights for GemPharmatech's next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mice lines within North America.Crown Bioscience, Inc., a JSR Life Sciences company, entered into a global licensing agreement with ERS Genomics Limited.
This agreement provided Crown Bioscience full permission to operate globally using ERS's foundational CRISPR/Cas9 patent portfolio for genetic editing. Under the terms of the agreement, Crown Bioscience widened its genetic modification capabilities.
Patient-Derived Xenograft Model Market Report Coverage and Deliverables
The "Patient-Derived Xenograft Model Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Patient-Derived Xenograft Model Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Patient-Derived Xenograft Model Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Patient-Derived Xenograft Model Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Patient-Derived Xenograft Model Market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Model Type, Tumor Type, Application, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The patient-derived xenograft model market is estimated to register a CAGR of 13.5% during the forecast period.
The patient-derived xenograft model market is projected to reach a value of US$ 1,119.36 million by 2031.
Noble Life Sciences, Charles River Laboratories International Inc, Crown Bioscience Inc, EPO Berlin-Buch GmbH, Hera BioLabs, Oncodesign Services, WuXi AppTec Co Ltd., XenTech SAS, and Shanghai LIDE Biotech. Co. Ltd. are among the key players operating in the patient-derived xenograft model market.
North America dominated the market in 2024.
The rising prevalence of cancer and growing demand for personalized medicine are noteworthy factors contributing to market growth.
The List of Companies - Patient-Derived Xenograft Model Market
- Charles River Laboratories International Inc.
- Noble Life Sciences
- Crown Bioscience Inc.
- Experimental Pharmacology & Oncology Berlin-Buch GmbH
- Hera Biolabs
- WuXi AppTec Co Ltd
- Oncodesign Services
- BioDuro LLC
- XenTech SAS
- Shanghai LIDE Biotech. Co. Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Patient-Derived Xenograft Model Market
Nov 2025
Carrier Testing Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), Medical Condition (Pulmonary Conditions, Hematological Conditions, Neurological Conditions, and Other Medical Conditions), End User (Hospital-Based Laboratories, Diagnostic Laboratories, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Medical Contract Manufacturing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Full-device Manufacturing, Sub-assembly and Components, and Materials-specific Services), Device Type (IVD Devices, Diagnostic Imaging Devices, Cardiovascular Devices, Drug Delivery Devices, Orthopedic Devices, Respiratory Care Devices, Ophthalmology Devices, Surgical Devices, Diabetes Care Devices, Dental Devices, Endoscopy and Laparoscopy Devices, Gynecology and Urology Devices, Neurology Devices, Patient Assistive Devices, and Others), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Human Albumin Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application [Therapeutic Applications (Liver and Kidney Diseases, Surgery, Hypovolemia and Hypoalbuminemia, and Others), Drug Delivery, Disease Diagnostics, Research, and Others], and End User (Hospitals and Clinics, Pharmaceutical and Biotechnological Companies, Research Institutes, Diagnostic Laboratories, Homecare Settings, and Others)
Nov 2025
Peritoneal Dialysis Equipment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Peritoneal Dialysis Solution, Peritoneal Dialysis Catheters, Peritoneal Dialysis Transfer Sets, and Others), Dialysis Type (Continuous Ambulatory Peritoneal Dialysis (CAPD), and Automated Peritoneal Dialysis (APD)), End User (In-Center Dialysis Settings, and Home Care Settings), and Geography
Nov 2025
Hemodialysis Equipment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Dialyzers, Dialysate, Access Products, and Others), End User (In-Center Dialysis Settings and Home Care Settings), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Urokinase API and Finished Dosage Forms Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Active Pharmaceutical Ingredient and Finished Dosage Forms), Manufacturing Process (Urine-derived, Cell Culture-based, and Recombinant Technology), Indication (Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), Catheter Occlusion, Myocardial Infarction (Heart Attack), Peripheral Arterial Occlusive Diseases, and Others), Distribution Channel (Hospital Pharmacies, Retail and Drug Stores, Direct Sales (API and FDF), and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Aesthetic Fillers and Exosomes Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type [Dermal Fillers (Calcium Hydroxylapatite, Hyaluronic Acid, Collagen, Poly-L-Lactic Acid, Polymethylmethacrylate (PMMA), Fat Fillers, and Others) and Exosome-Based Aesthetic Products (Human-derived, Animal-derived, and Plant-derived)], Route of Administration [Injectable, Topical (Serum, Cream, Mask, and Others)], Application (Skin Rejuvenation, Wrinkle Reduction and Fine Line Correction, Facial Contouring, Lip Augmentation, Scar and Pigmentation, Post-procedure Recovery, Hair Restoration, and Others), End User (Hospitals, Dermatology Clinics, Medical Spas, and Others), and Geography (North America, Europe, and Middle East)
Nov 2025
Veterinary Diagnostics Products Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Kits and Reagents [ELISA Test Kits, Antibodies Test Kits, Polymerase Chain Reaction (PCR) Test Kits, Hematology Test Kits, Biochemistry Test Kits, Immunoassay Reagents, and Others]and Analyzers [Biochemistry Analyzers, Hematology Analyzers, Immunoassay Analyzers, PCR Analyzers, and Others]), Animal Type (Companion Animal [Dogs, Cats, Horses, and Others] and Livestock Animal [Cattles, Pigs, Poultry, and Others]), Application (Infectious Diseases [Rabies, Avian Influenza, Leishmania, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection, and Others] and Non-Infectious Diseases [Pneumonia, Gastritis, Bronchitis, and Others]), End User (Public Healthcare Facilities and Private Healthcare Facilities), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)